Antiischemic effectiveness of ivabradine and its impact on microcirculation in patients with coronary heart disease associated with chronic obstructive pulmonary disease

Aim. To assess the antiischemic effectiveness of an If-channel inhibitor ivabradine and its impact on systemic and myocardial microcirculation, left Ventricular diastolic dysfunction, and psychosocial parameters in patients with coronary heart disease (CHD) associated with chronic obstructive pulmonary disease (COPD). Material and methods. The study included 82 patients with CHD and Functional Class II-III stable angina. In 47,6% of the participants, CHD was associated with Stage 1-3 COPD. Results. It was demonstrated that the If-channel inhibitor ivabradine is the medication of choice for patients with a combination of CHD and COPD. Ivabradine therapy was both effective and safe, and did not negatively affect the clinical course of COPD. Russ J Cardiol 2012, 4 (96): 62-68